BridgeMD
New treatment option for Septic Shock
Official title Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C
ClinicalTrials.gov ID: NCT06749756
What this study is testing
What is vitamin B6+ Vitamin B12 +vitamin C?
vitamin B6+ Vitamin B12 +vitamin C is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for septic shock.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Sepsis is a kind of disease with high morbidity and mortality in ICU. At present, there is no specific treatment, and its pathogenesis is mainly excessive oxidative stress.
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Age ≥18 and \< 85 years old
- Admitted to ICU
- Diagnosis of patients with SEPSIS 3.0 (diagnostic criteria) 4, SOFA score is 2-13 points 5\. Obtain the informed consent of the subject or his family
You likely can't join if
- Patients have absolute contraindications such as vitamin allergy
- Patients with a history of gout
- Death is expected within 24 hours
- Pregnant women
- Use hydroprednisone or other equivalent dose hormones \> 200mg/d within 24 hours
- Without the informed consent of the patient or his/her representative
See the full eligibility criteria
- Age ≥18 and \< 85 years old
- Admitted to ICU
- Diagnosis of patients with SEPSIS 3.0 (diagnostic criteria) 4, SOFA score is 2-13 points 5\. Obtain the informed consent of the subject or his family
- Patients have absolute contraindications such as vitamin allergy
- Patients with a history of gout
- Death is expected within 24 hours
- Pregnant women
- Use hydroprednisone or other equivalent dose hormones \> 200mg/d within 24 hours
- Without the informed consent of the patient or his/her representative
- Patients with a history of scleroderma
- Patients with a history of vasculitis
- Patients with oral mucosal diseases
- Patients with severe difficulty in opening their mouth and unable to detect sublingual microcirculation
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Sichuan, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.